Welcome to our dedicated page for Envveno Medical Corporation SEC filings (Ticker: NVNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the FDA journey of a novel venous valve is challenging—especially when enVVeno Medical Corporation’s pivotal trial data, PMA module responses, and financing details are scattered across dense SEC filings. If you have ever asked, “Where can I find the latest enVVeno Medical insider trading Form 4 transactions or the newest 8-K material events explained?” this page solves that problem.
Stock Titan’s AI reads every submission the moment it hits EDGAR, then serves plain-English answers. Need the enVVeno Medical quarterly earnings report 10-Q filing without wading through accounting jargon? Our summaries highlight cash burn, R&D spend, and trial milestones. Wondering whether management is buying shares? Real-time alerts surface enVVeno Medical Form 4 insider transactions alongside context so you can gauge executive conviction.
All core documents are here and continuously updated:
- 10-K annual report—get the enVVeno Medical annual report 10-K simplified to understand long-term strategy and regulatory timelines.
- 10-Q quarterly updates—compare enrollment progress with last quarter in seconds.
- 8-K releases—see FDA feedback or financing announcements the moment they post.
- DEF 14A proxy—explore enVVeno Medical proxy statement executive compensation details.
- Form 4—track enVVeno Medical executive stock transactions Form 4 in real time.
From “understanding enVVeno Medical SEC documents with AI” to detailed enVVeno Medical earnings report filing analysis, our platform turns complex disclosures into actionable insight so you can focus on decisions—not document hunts.
Kingdon group disclosed a passive holding in enVVeno Medical Corporation (NVNO). The filing reports that Kingdon Capital Management, L.L.C. and affiliated entities and individual Mark Kingdon together hold shared voting and dispositive power over 1,359,261 shares, representing 7.1% of the outstanding common stock. M. Kingdon Offshore Master Fund, L.P. and Kingdon GP, LLC each report 1,265,845 shares (6.6%). The filing states the securities are owned by advisory clients and were not acquired to change or influence control of the issuer. Signatures from authorized representatives and exhibits (Joint Filing Agreement and Control Person Identification) are attached.
FAQ
What is the current stock price of Envveno Medical Corporation (NVNO)?
What is the market cap of Envveno Medical Corporation (NVNO)?
